Genentech, Inc.

Boehringer Ingelheim International Gmbh

University of North Carolina at Chapel Hill

Other

Boehringer Ingelheim Gmbh

Genetech, Inc.

Immuno Aktiengesellschaft Fur Chemisch-medizinische Produkte

Kurt Zatloukal

David T Curiel

Matthew Cotten

Ernst Wagner

Max L Birnstiel

Berndt Oberhauser

Christian Plank

Walter G Schmidt

Karl-Heinz Heider

Walter G M Schmidt

Christine Beham-Schmid

Hans P Dinges

The invention relates to a method for diagnosing and treating Hodgkin's lymphomas (lymphogranulomatosis) which is based on the expression of the variant exon v10 of the CD44 gene as a molecular marker or target. There is a significant correlation between v10 expression and the stage and prognosis of the disease. In a preferred embodiment, v10-specific antibody molecules are used to measure the expression of the exon in samples. In another preferred embodiment, radiolabelled v10-specific antibodies are used to treat Hodgkin's lymphomas.

Method for diagnosis and therapy of Hodgkin's lymphomas

A composition for the transfection of higher eucaryotic cells, comprising complexes of nucleic acid, a substance having an affinity for nucleic acid and optionally an internalizing factor, contains an endosomolytic agent, e.g. a virus or virus component, which may be conjugated. The endosomolytic agent, which is optionally part of the nucleic acid complex, is internalized into the cells together with the complex and releases the contents of the endosomes into the cytoplasm, thereby increasing the gene transfer capacity. Pharmaceutical preparations, transfection kits and methods for introducing nucleic acid into higher eucaryotic cells by treating the cells with the composition are also disclosed.

Composition for introducing nucleic acid complexes into higher eucaryotic cells

Composition for introducing nucleic acid complexes into higher

Composition comprising an endosomolytic agent for introducing nucleic

A biopsy device including a two- or multi-lumen biopsy cannula has a biopsy channel of constant cross section over its entire length and at least one application channel. On its proximal end, it is provided with connection facilities for an aspiration device and at least one application device. In order to enable the collection of tissue specimens of an unchanged structure with the most careful handling possible of the tissue and the application of auxiliary substances into the puncture channel without tissue specimens getting into the application cannula and obstructing the same, the cutting edge is formed by an acute-angularly designed end of the biopsy channel wall alone. At least one application channel is formed by a tube eccentrically slipped over the biopsy channel wall. The biopsy channel wall projects out of the tube with its cutting edge and the tube end encloses an obtuse angle with the biopsy channel.

Biopsy device

Growing community of inventors

Vienna, Austria

Kurt Zatloukal